CAR T-cells for acute lymphoblastic leukemia (ALL) treatment are promising, with a number of different agents in development. Here, Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the status of the Phase I/II ZUMA-3 trial of KTE-C19 for relapsed/refractory ALL. He also highlights his hopes for the study and the use of approaches such as minimal residual disease (MRD) measurement to guide therapy such as this. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.
Status of the ZUMA-3 trial of CAR T-cell product KTE-C19 for R/R ALL
